Pacific Biosciences of California Inc

PACB remains in an early Stage 1 consolidation that has just broken above its multi-month range on strong volume, signaling potential transition into a Stage 2 advance. However, price is extended above the rising short-term EMAs and in overbought territory, making immediate execution unfavorable. We will wait for a pullback into the reclaimed resistance zone around the 9/21 EMAs and the 50 SMA for optimal participation in the emerging advance.

• ↑Q1 consumables revenue $21.8M (+9% YoY) offsets flat $37.2M total revenue.
• ↑SparkNEXT platform poised to lower sequencing costs and drive Revio system demand.
• ↓Q1 instrument revenue slid 12% YoY to $9.7M due to academic funding cuts.